Billionaire Profile
Jorge Gallardo Ballart
Global Rank
#2803

Image: Unsplash Contributor | Unsplash License | via Unsplash

Jorge Gallardo Ballart

CEO, Pharmaceuticals
SPAIN
Real-Time Net Worth
$1.255B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
-0.36% (24h)
Age
84
Source
pharmaceuticals
Industry
Healthcare
Citizenship
SPAIN

Biography

Jorge Gallardo Ballart, born in 1941, is a Spanish billionaire and a key figure in the pharmaceutical industry. His wealth stems from his role at Almirall, a company founded by his father. As executive president, he played a crucial role in the company's expansion and internationalization. As of February 1, 2026, his net worth is estimated at $1.3 billion, placing him among the world's wealthiest individuals. Gallardo's career has been marked by significant milestones and leadership within the pharmaceutical sector, contributing to Almirall's success and establishing his legacy.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life

Jorge Gallardo Ballart was born on September 26, 1941, in Barcelona, Spain. His father, Antonio Gallardo Carrera, founded the pharmaceutical company Almirall in 1943. From a young age, Jorge was immersed in the world of pharmaceuticals, learning the values of entrepreneurship and innovation that would shape his future.

Rise to Success

Jorge Gallardo Ballart joined Almirall in 1965, after studying industrial engineering. After his father died in 1988, Jorge and his brother Antonio took over the company, transforming the family business to a prominent pharmaceutical company in Europe. Under Jorge's leadership, Almirall has expanded its global footprint, particularly in dermatology, solidifying his position as a leader in the industry. The company became listed in 2007, and the family controls it through holdings.

Key Business Strategies

Almirall's success under Jorge Gallardo's guidance is attributed to several key strategies. The company has prioritized innovation, allocating a significant portion of its revenue to research and development. Almirall's strategic acquisitions and a focus on dermatology and respiratory franchises have further fueled its growth. The company has also fostered a culture of growth and empowerment, enabling it to adapt quickly to new business opportunities and market trends.

Philanthropy

While specific details on his current philanthropic endeavors are not available through the search results, the Gallardo family has a history of supporting various initiatives, including the creation of the Gallardo Family Group, which emphasizes family togetherness and contributing to healthcare and the success of family enterprises.

Career Milestones

1965

Joined Almirall

Began his career at Almirall after completing his studies in Industrial Engineering.

1972

PhD in Industrial Engineering

Earned a doctorate in Industrial Engineering from the Barcelona Higher Technical School of Industrial Engineers.

1988

Took over Almirall

Became the head of Almirall with his brother following their father's death.

1998-2018

President of EFPIA

Served as President of the European Federation of Pharmaceutical Industries and Associations.

2007

Almirall IPO

Almirall became a publicly traded company.

2011

Executive Chairman

Became Executive Chairman of Almirall.

2022

Transition of Power in Family Governance

Started the transition to the third generation of the Gallardo family.

Philanthropy & Social Impact

Healthcare

Gallardo Family Group

Undisclosed

The Gallardo family group is committed to family togetherness and the success of family enterprises, especially in healthcare.

Business Philosophy & Leadership

Leadership Principles

Innovation

Emphasizing innovation in all aspects of the business to stay ahead in the pharmaceutical industry.

Commitment to R&D

Allocating significant resources to research and development for long-term growth.

Focus on Dermatology

Prioritizing dermatology and respiratory franchises, establishing a strong market position.

Controversies & Challenges

2018

Financial Setbacks in the US

Almirall's expansion in the US, particularly with the acquisition of Aqua, faced challenges, with sales declining and the company experiencing losses.